FIELD: pharmaceutical industry.
SUBSTANCE: employment of title compounds is based on their ability of inhibiting NF-κB activation cascade. Invention provides compositions with these acids to treat patients suffering from diseases caused by formation of NF-κB.
EFFECT: expanded therapeutical possibilities.
6 cl, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| IBUPROFEN THIOETHER AS INHIBITOR DEPENDING UPON NF-KB FORMATION OF INFLAMMATION AND PAIN MEDIATORS | 1998 |
|
RU2204388C2 |
| METHOD FOR INHIBITING NUCLEAR KAPPA B FACTOR WITH USING 2-ETHYL-6-METHYL-3-HYDROXIPIRIDINIUM L-2,6-DIAMINOHEXANOATE IN CULTURE OF CELLS | 2017 |
|
RU2669348C1 |
| NEW TREATMENT OF MULTIPLE SCLEROSIS (MS) | 2011 |
|
RU2595861C2 |
| METHOD FOR INHIBITING NUCLEAR FACTOR KAPPA B WITH USE OF 5-HYDROXYNICOTINATE 3-(2,2,2-TRIMETHYLHYDRAZINIUM) POTASSIUM PROPIONATE IN CELL CULTURE | 2017 |
|
RU2674443C1 |
| METHOD OF INHIBITING KAPPA NUCLEAR FACTOR WITH THE USE OF POTASSIUM 5-HYDROXYNICOTINATE IN A CELL CULTURE | 2017 |
|
RU2675693C1 |
| ANALGETIC COMPOSITION AND A METHOD OF ANALGETIC EFFECT ATTAINMENT IN HUMAN | 1993 |
|
RU2125873C1 |
| PHARMACEUTICAL COMBINATION AND USING IT | 2011 |
|
RU2575775C2 |
| (R)-2-ARYLPROPIONIC ACID OMEGA-AMINOALKYLAMIDES AS INHIBITORS OF POLYMORPHONUCLEAR AND MONONUCLEAR CELL HEMOTAXIS, METHOD FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2002 |
|
RU2272024C2 |
| 2-ARYLPROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF | 2002 |
|
RU2317075C2 |
| AMIDINES AND THEIR DERIVATIVE, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF | 2004 |
|
RU2375346C2 |
